zavegepant (Zavzpret)

From Aaushi
Jump to navigation Jump to search
[1]

Indications

Dosage

Pharmacokinetics

  • rapid onset of action ~15 minutes

Mechanism of action

More general terms

References

  1. ↑ Lipton RB, Croop R, Stock DA et al Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo- controlled multicentre trial. Lancet Neurol. 2023 Mar;22(3):209-217. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36804093
Retrieved from "https://aaushi.info/w/index.php?title=A58056&oldid=1155174"